![Francine Gervais](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Francine Gervais
Corporate Officer/Principal chez McGill University
Profil
Francine Gervais is a Professor at McGill University.
She was previously a Vice President-Research & Development at BELLUS Health, Inc. and a SVP & Vice President-Pharmaceutical Development at PainCeptor Pharma Corp.
She holds a doctorate degree from the University of Montréal.
Postes actifs de Francine Gervais
Sociétés | Poste | Début |
---|---|---|
McGill University | Corporate Officer/Principal | - |
Anciens postes connus de Francine Gervais
Sociétés | Poste | Fin |
---|---|---|
BELLUS HEALTH | Directeur Technique/Scientifique/R&D | - |
PainCeptor Pharma Corp.
![]() PainCeptor Pharma Corp. Pharmaceuticals: MajorHealth Technology PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada. | Corporate Officer/Principal | - |
Formation de Francine Gervais
University of Montréal | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
PainCeptor Pharma Corp.
![]() PainCeptor Pharma Corp. Pharmaceuticals: MajorHealth Technology PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada. | Health Technology |
BELLUS Health, Inc.
![]() BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada. | Health Technology |